PUBLISHER: Polaris Market Research | PRODUCT CODE: 1786790
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1786790
U.S. Antifungal Drugs Market Size, Share, Trend, Industry Analysis Report By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), By Indication, By Dosage Form, By Distribution Channel - Market Forecast, 2025-2034
The U.S. antifungal drugs market size is expected to reach USD 7.96 billion by 2034, according to a new study by Polaris Market Research. The report "U.S. Antifungal Drugs Market Size, Share, Trend, Industry Analysis Report By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), By Indication, By Dosage Form, By Distribution Channel - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The U.S. antifungal drugs market focuses on the development, distribution, and utilization of medications designed to treat fungal infections ranging from superficial to invasive forms. Demand is largely driven by the growing prevalence of fungal diseases in immunologically vulnerable populations, including patients undergoing cancer therapy, organ transplantation, or long-term immunosuppressive treatment. The rising incidence of hospital-acquired fungal infections, particularly in intensive care and surgical settings, is also creating significant therapeutic demand. Drug development is shifting toward more targeted, low-toxicity compounds that address resistance issues, especially in cases involving Candida and Aspergillus species.
Oral, topical, and intravenous formulations continue to evolve through advances in delivery technologies that improve treatment adherence and clinical outcomes. Increased emphasis on antifungal stewardship programs is encouraging more rational prescribing and boosting the uptake of newer therapeutic classes. Opportunities are emerging through the expansion of outpatient treatment, direct-to-consumer sales for topical applications, and rising interest in fixed-dose combinations. Ongoing innovation in formulation science and clinical diagnostics is helping identify infections earlier and tailor treatment more precisely, improving therapeutic success. Strong support from healthcare institutions, insurers, and regulatory agencies is accelerating product launches and facilitating patient access. The competitive environment remains dynamic, with pharmaceutical firms prioritizing lifecycle management, strategic collaborations, and niche-focused R&D to secure market advantage. The U.S. antifungal drugs market is poised for steady growth, driven by the need for safe, effective, and accessible antifungal therapies that can meet the demands of acute and chronic care environments.
U.S. Antifungal Drugs Market Report Highlights
By drug class, the azoles drug segment accounted for ~48% of the revenue share in 2024 due to their broad-spectrum efficacy against both superficial and systemic fungal infections. Its established clinical safety makes it a preferred treatment across healthcare settings.
Based on indication, the Candidiasis segment held the largest revenue share in 2024 due to its widespread occurrence across various patient populations.
A few key players include Abbott; Astellas Pharma, Inc.; Bayer AG; Enzon Pharmaceuticals, Inc.; Glenmark; GSK plc; Merck & Co., Inc.; Novartis AG; Pfizer, Inc.; and Sanofi.
Polaris Market Research has segmented the U.S. antifungal drugs market report on the basis of drug class, indication, dosage form, and distribution channel:
By Drug Class Outlook (Revenue, USD Billion, 2020-2034)
Azoles
Echinocandins
Polyenes
Allylamines
Others
By Indication Outlook (Revenue, USD Billion, 2020-2034)
Dermatophytosis
Aspergillosis
Candidiasis
Others
By Dosage Form Outlook (Revenue, USD Billion, 2020-2034)
Oral Drugs
Ointments
Powders
Others
By Distribution Channel Outlook (Revenue, USD Billion, 2020-2034)
Hospital Pharmacies
Retail Pharmacies
Others
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. U.S. Antifungal Drugs Market Insights
- 4.1. U.S. Antifungal Drugs Market - Market Snapshot
- 4.2. U.S. Antifungal Drugs Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. High Prevalence of Immunocompromised Patients
- 4.2.1.2. Increasing Hospital-Acquired Fungal Infections
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High costs of the products
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. U.S. Antifungal Drugs Market Power Rating Trends
- 4.6. Value Chain Analysis
5. U.S. Antifungal Drugs Market, by Drug Class
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. U.S. Antifungal Drugs Market, by Drug Class, 2020-2034 (USD Billion)
- 5.3. Azoles
- 5.3.1. U.S. Antifungal Drugs Market, by Azoles, 2020-2034 (USD Billion)
- 5.4. Echinocandins
- 5.4.1. U.S. Antifungal Drugs Market, by Echinocandins, 2020-2034 (USD Billion)
- 5.5. Polyenes
- 5.5.1. U.S. Antifungal Drugs Market, by Polyenes, 2020-2034 (USD Billion)
- 5.6. Allylamines
- 5.6.1. U.S. Antifungal Drugs Market, by Allylamines, 2020-2034 (USD Billion)
- 5.7. Others
- 5.7.1. U.S. Antifungal Drugs Market, by Others, 2020-2034 (USD Billion)
6. U.S. Antifungal Drugs Market, by Indication
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. U.S. Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 6.3. Dermatophytosis
- 6.3.1. U.S. Antifungal Drugs Market, by Dermatophytosis, 2020-2034 (USD Billion)
- 6.4. Aspergillosis
- 6.4.1. U.S. Antifungal Drugs Market, by Aspergillosis, 2020-2034 (USD Billion)
- 6.5. Candidiasis
- 6.5.1. U.S. Antifungal Drugs Market, by Candidiasis, 2020-2034 (USD Billion)
- 6.6. Others
- 6.6.1. U.S. Antifungal Drugs Market, by Others, 2020-2034 (USD Billion)
7. U.S. Antifungal Drugs Market, by Dosage Form
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. U.S. Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 7.3. Oral Drugs
- 7.3.1. U.S. Antifungal Drugs Market, by Oral Drugs, 2020-2034 (USD Billion)
- 7.4. Ointments
- 7.4.1. U.S. Antifungal Drugs Market, by Ointments, 2020-2034 (USD Billion)
- 7.5. Powders
- 7.5.1. U.S. Antifungal Drugs Market, by Powders, 2020-2034 (USD Billion)
- 7.6. Others
- 7.6.1. U.S. Antifungal Drugs Market, by Others, 2020-2034 (USD Billion)
8. U.S. Antifungal Drugs Market, by Distribution Channel
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. U.S. Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.3. Hospital Pharmacies
- 8.3.1. U.S. Antifungal Drugs Market, by Hospital Pharmacies, 2020-2034 (USD Billion)
- 8.4. Retail Pharmacies
- 8.4.1. U.S. Antifungal Drugs Market, by Retail Pharmacies, 2020-2034 (USD Billion)
- 8.5. Others
- 8.5.1. U.S. Antifungal Drugs Market, by Others, 2020-2034 (USD Billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. Abbott
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Astellas Pharma, Inc.
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Bayer AG
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Enzon Pharmaceuticals, Inc.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Glenmark
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. GSK plc
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Merck & Co., Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Novartis AG
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Pfizer, Inc
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Sanofi
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
List of Tables:
- Table 1 U.S. Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- Table 2 U.S. Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- Table 3 U.S. Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- Table 4 U.S. Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
List of Figures:
- Figure 1. U.S. Antifungal Drugs Market, 2020-2034 (USD Billion)
- Figure 2. Integrated Ecosystem
- Figure 3. Research Methodology: Top-Down & Bottom-Up Price
- Figure 4. Market by Geography
- Figure 5. Porter's Five Forces
- Figure 6. Market by Drug Class
- Figure 7. U.S. Antifungal Drugs Market, By Drug Class, 2024 & 2034 (USD Billion)
- Figure 8. Market by Indication
- Figure 9. U.S. Antifungal Drugs Market, By Indication, 2024 & 2034 (USD Billion)
- Figure 10. Market by Distribution Channel
- Figure 11. U.S. Antifungal Drugs Market, by Distribution Channel, 2024 & 2034 (USD Billion)
- Figure 12. Market by Dosage Form
- Figure 13. U.S. Antifungal Drugs Market, by Dosage Form, 2024 & 2034 (USD Billion)
